<?xml version="1.0" encoding="UTF-8"?>
<p>Consequently, there is a concern that IBD patients are at greater risk of developing COVID‐19 and at increased risk of progressing to a more severe clinical course or even death compared to the general population. In addition, if an IBD patient develops COVID‐19, there is a lack of guidance on medication management and concern regarding drug interactions if trial medications are utilised to treat COVID‐19.</p>
